Compare AbCellera Biologics Inc (ABCL) vs Carlyle Group Inc (CG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Carlyle Group Inc — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Carlyle Group Inc trades at $42.99 (market cap $15.84B). The key difference: Carlyle Group Inc is far larger — about 6.7× AbCellera Biologics Inc's market cap, and Carlyle Group Inc pays a 3.18% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CG | |
|---|---|---|
Market Cap | $2.35B | $15.84B |
Sector | Health | Financials |
52-Week High | $8.12 | $69.35 |
52-Week Low | $2.78 | $40.52 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Carlyle Group (CG) trades at $44.01, up 2.76% with a P/E of 30.16 and P/S of 5.61. Recent earnings show mixed results with Q4 2025 beat but Q1 2026 miss. Technical indicators signal bearish momentum with RSI at 76.93 suggesting overbought conditions. The company maintains strong analyst support with 14 buy ratings and a $59.60 consensus price target, representing 35% upside potential from current levels.
Carlyle demonstrates solid profitability with 18.85% net margin and 9.95% ROE, though revenue declined to $3.21B in 2025. Key risks include volatile cash flow from operations and execution challenges in fundraising targets. The stock offers growth potential through strategic acquisitions like MAI Capital Management, but investors should monitor earnings consistency and private credit exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
